Zoe Biosciences develops novel therapies focused on treating cardiometabolic disease. The company leverages extensive research to create drug candidates targeting specific pathways like PAI-1 and APJ. Their work addresses significant public health challenges associated with cardiometabolic aging and related conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Age-related diseases and the aging process itself are significant contributors to declining health and reduced lifespan. Cellular senescence and metabolic dysfunction are key biological mechanisms driving age-related health decline.
Solution
Zoe Biosciences is developing therapeutics that target the fundamental biological mechanisms of aging, specifically cellular senescence and metabolic dysfunction. By addressing these core drivers of age-related diseases, the company aims to develop interventions that can extend healthy lifespan. Their therapeutic approach focuses on modulating cellular processes to mitigate the negative effects of aging and promote overall health. The goal is to create treatments that not only address specific age-related diseases but also improve overall physiological function and resilience.
Target Audience
The primary target audience includes individuals at risk of or affected by age-related diseases, as well as healthcare providers seeking innovative treatments to extend healthy lifespan.
Features
- Focus on therapeutics targeting cellular senescence.
- Development of interventions to address metabolic dysfunction associated with aging.
- Modulation of cellular processes to mitigate the negative effects of aging.
- Aim to improve overall physiological function and resilience.